| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $2.3M | -1.0% |
| SG&A Expense | $1.4M | -18.3% |
| Operating Income | -$3.7M | +8.4% |
| Net Income | -$2.9M | -102.6% |
| EPS (Basic) | -$0.01 | -80.0% |
| EPS (Diluted) | -$0.01 | -80.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $65K | +33.6% |
| Current Assets | $77K | -5.6% |
| Total Assets | $1.4M | +1.3% |
| Current Liabilities | $3.0M | +34.9% |
| Total Liabilities | $5.1M | +20.7% |
| Stockholders' Equity | -$3.7M | -30.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$845K | +15.8% |
| Capital Expenditures | $69K | -3.1% |
| Investing Cash Flow | -$137K | -18.6% |
| Financing Cash Flow | $999K | -11.4% |
| Free Cash Flow | -$914K | +15.0% |